ImClone Systems Incorporated Reports Data on its Cancer Therapeutic, C225, at American Society of Clinical Oncology Meeting.LOS ANGELES--(BW HealthWire)--May 18, 1998--ImClone Systems Incorporated (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : IMCL IMCL International Making Cities Livable IMCL Inter Marine Container Lines IMCL International Management Consultants Ltd. IMCL Indraprastha Medical Corp Ltd (India) IMCL Imperial Majesty Cruise Line ) today announced the presentation of data at the 34th annual meeting of the American Society of Clinical Oncology American Society of Clinical Oncology, or ASCO, is an organization that represents all clinical oncologists. Every year, ASCO holds a large symposium where physicians and researchers meet to convey and discuss research and ideas. concerning the Company's lead cancer therapeutic, C225, an inhibitor of the epidermal growth factor receptor This article is about a cell suface receptor. For estimated measure of kidney function (eGFR), see Glomerular filtration rate. The epidermal growth factor receptor (EGFr). As presented by a research team headed by Francisco Robert, M.D., Director Comprehensive Cancer Center University of Alabama at Birmingham UAB began in 1936 as the Birmingham Extension Center of the University of Alabama. Because of the rapid growth of the Birmingham area, it was decided that an extension program for students who had difficulties which prevented them from studying in Tuscaloosa was needed. , combination treatment using C225 and radiotherapy resulted in major responses in all 12 evaluable patients enrolled in a Phase Ib/IIa study of advanced squamous cell squamous cell n. A flat, scalelike epithelial cell. head and neck cancer. Based on these trial results, ImClone intends to initiate Phase III clinical trials for patients with head and neck cancer during 1998. Harlan W. Waksal, M.D., Executive Vice President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of ImClone Systems commented, "We believe these findings are suggestive of potential clinical benefit for patients with head and neck cancer. While recent published data for radiotherapy alone have shown about a 30 to 40 percent major (complete or partial) response rate in this patient population, our early data for C225 demonstrate a major response rate of 100 percent. Further, this combination was well-tolerated and represents an important new approach to the treatment of this disease. It is now hoped that Phase III clinical studies will further expand and validate these findings." C225 is a monoclonal antibody which inhibits activity of epidermal growth factor receptor (EGFr) associated with cancer cell growth in renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. , epidermoid carcinoma, and other cancers. ImClone is currently studying C225 in head and neck cancer patients in Phase Ib/IIa dose-escalation trials in combination with other anti-cancer therapies, including chemotherapy and radiation. The Company is also conducting a Phase II C225 trial for the treatment of patients with metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. renal cell carcinoma. ImClone Systems has two oncology products in late stage clinical development and is advancing earlier drug candidates to the clinical stage. In addition to C225, ImClone's other late stage clinical development program is an anti-cancer vaccine, BEC2. ImClone and its corporate partner, Merck KGaA, are initiating a Phase III multinational trial to study BEC2 in small cell lung cancer Lung Cancer, Small Cell Definition Small cell lung cancer is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description Lung cancer is divided into two main types: small cell and non-small cell. patients. In preclinical research, the Company is evaluating the therapeutic potential of its anti-FLK-1/KDR monoclonal antibody as an anti-angiogenic agent especially against tumors known to secrete vascular endothelial growth factor Vascular endothelial growth factor (VEGF) is an important signaling protein involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). . ImClone Systems Incorporated, headquartered in New York, is a biopharmaceutical company developing novel therapeutic products including interventional therapeutics, cancer vaccines and blood cell growth factors for the treatment of cancer and cancer-related disorders. -0- Except for the historical information contained herein, the matters discussed in this news release may include forward-looking statements. Actual results may differ materially from those predicted in such forward-looking statements due to the risks and uncertainties inherent in the Company's business, including, without limitation, risks and uncertainties in obtaining and maintaining regulatory approval, market acceptance of and continuing demand for the Company's products, the impact of competitive products and pricing, and the Company's ability to obtain additional financing to support its operations. The Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. CONTACT: ImClone Systems Incorporated Andrea F. Rabney Senior Director of Corporate Development and Investor Relations (212) 645-1405 or Burns McClellan, Inc. Jonathan M. Nugent (investors) Justin Jackson (media) (212) 213-0006 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion